For example, based on the PALOMA-3 trial, O’Leary et al. [11] detected RB1 mutations in the plasma of ER+/HER2− advanced breast cancer patients at the end of treatment, suggesting the acquisition or selection of genomic aberrations under pressure from palbociclib. The gene discussed is ERBB2; the disease is breast carcinoma.